Schering Corporation

Merck Sharp + Dohme Corp.

Merck Sharpe & Dohme Corp.

Holly Cherwinski

Joseph H Phillips

Yi Heng Chen

Barbara Joyce-Shaikh

Michael Eric Bigler

Adele Wang

Leonard G Presta

Daniel J Cua

Daniel Cua

Jonathon D Sedgwick

The present invention provides antibodies and antigen-binding fragments thereof that bind PI16 and block binding of ILT3 to PI16.

P116 antibodies

The present invention provides antibodies and antigen-binding fragments thereof that bind ILT3, ILT3 ligand (i.e., PI16) or a complex between ILT3 and the ILT3 ligand. Methods for determining whether ILT3 and the ILT3 ligand bind together or whether a substance agonizes or antagonizes such binding are also provided.

ILT3 ligand

Provided are methods for modulating activity of the immune system using agonists or antagonists of a CD200 receptor. Also provided are methods of treatment and diagnosis of immune disorders.

Methods of modulating CD200 receptors

The invention relates generally to the field of immunology, in particular, to bispecific antibodies. Methods for designing a bispecific antibody for use in treating diseases relating to the immune system are disclosed. Specific examples relate to bispecific antibodies which recognize an activating receptor and an inhibiting receptor.

Use of bispecific antibodies to regulate immune responses

The present invention relates to binding compounds specific for the human inhibitory CD200R and uses thereof. More specifically, the invention relates to antibodies that recognize the human inhibitory CD200R and modulates its activity in inflammatory and autoimmune disorders.

Growing community of inventors

Boulder Creek, CA, United States of America

Holly Cherwinski